These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 33574819)
21. Evolution of COVID-19 in patients with autoimmune rheumatic diseases. Pang R; Zhao J; Gan Z; Hu Z; Xue X; Wu Y; Qiao Q; Zhong A; Xia X; Liao H; Wang Z; Zhang L Aging (Albany NY); 2020 Dec; 12(23):23427-23435. PubMed ID: 33289698 [TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Cook C; Patel NJ; D'Silva KM; Hsu TY; DiIorio M; Prisco L; Martin LW; Vanni K; Zaccardelli A; Todd D; Sparks JA; Wallace ZS Ann Rheum Dis; 2022 Feb; 81(2):289-291. PubMed ID: 34489304 [No Abstract] [Full Text] [Related]
23. Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. Atagündüz P; Keser G; Soy M Front Immunol; 2021; 12():734279. PubMed ID: 35154066 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385 [No Abstract] [Full Text] [Related]
25. Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. Senécal JL; Chartier S; Rothfield N J Rheumatol; 1995 May; 22(5):868-75. PubMed ID: 8587074 [TBL] [Abstract][Full Text] [Related]
26. Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Sher EK; Ćosović A; Džidić-Krivić A; Farhat EK; Pinjić E; Sher F Life Sci; 2023 Apr; 319():121531. PubMed ID: 36858313 [TBL] [Abstract][Full Text] [Related]
27. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. Costagliola G; Spada E; Consolini R Pediatr Rheumatol Online J; 2021 May; 19(1):68. PubMed ID: 33947420 [TBL] [Abstract][Full Text] [Related]
32. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Shin YH; Shin JI; Moon SY; Jin HY; Kim SY; Yang JM; Cho SH; Kim S; Lee M; Park Y; Kim MS; Won HH; Hong SH; Kronbichler A; Koyanagi A; Jacob L; Smith L; Lee KH; Suh DI; Lee SW; Yon DK Lancet Rheumatol; 2021 Oct; 3(10):e698-e706. PubMed ID: 34179832 [TBL] [Abstract][Full Text] [Related]
33. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Yousefghahari B; Navari S; Sadeghi M; Soleimaniamiri S; Soleimaniamiri M; Heidari B; Babaei M; Ghodrati K; Guran A; Gholinia H Clin Rheumatol; 2021 Oct; 40(10):4309-4315. PubMed ID: 34052904 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481 [TBL] [Abstract][Full Text] [Related]
35. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H Front Immunol; 2021; 12():677957. PubMed ID: 34335579 [TBL] [Abstract][Full Text] [Related]
36. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Dotan A; Muller S; Kanduc D; David P; Halpert G; Shoenfeld Y Autoimmun Rev; 2021 Apr; 20(4):102792. PubMed ID: 33610751 [TBL] [Abstract][Full Text] [Related]
37. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Vahabi M; Ghazanfari T; Sepehrnia S Int Immunopharmacol; 2022 Nov; 112():109183. PubMed ID: 36182877 [TBL] [Abstract][Full Text] [Related]